Glenmark Pharmaceuticals Inc., USA, a part of Glenmark Pharmaceuticals Limited, has made a major step into the injectable drug market. In November 2025, the company launched its 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL Single-Dose Vial, entering a market with significant yearly sales.
The new product is bioequivalent and therapeutically similar to Abbott Laboratories' reference drug. This launch positions Glenmark to compete in a market that, according to IQVIA sales data, had annual sales of around USD 63.8 million for the 12 months ending in August 2025.
Marc Kikuchi, President and Business Head for North America, threw light on the importance of this launch, noting that it expands Glenmark's injectable portfolio. He highlighted that the strategic move reflects the company’s commitment to offering quality as well as affordable alternatives for patients across the board.
Although the company has not disclosed specific financial projections for this product, entering a market with annual sales of USD 63.80 million indicates high potential for revenue growth. Investors as well as analysts will probably be watching closely to see how this launch affects Glenmark’s future financial performance.
In accordance with regulatory rules, Glenmark has closed its trading window from September 30, 2025, to November 16, 2025. This showcases the company’s directors and other key individuals, as per the "Code of Conduct for Prevention of Insider Trading" and SEBI guidelines.
